This case centers around the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The results of the dialogue would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil.
The Flaxil Label (C) Debrief and Endnotes case solution
The discussion is quite qualitative and differs from the typical price negotiation with which students are familiar. Nonetheless, at position was the security of millions of patients and $500 million in Flaxil sales. The nutritional supplement features an epilogue to the A case.
PUBLICATION DATE: August 24, 2008 PRODUCT #: 909003-PDF-ENG
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
Gene Research the Mapping of Life and the Global Economy
HR Restructuring at Nissan Motor Company
John D. Rockefeller: The Richest Man in the World
CFR Pharmaceuticals: Potential Synergies in Africa
Difficult Conversations: How to Address What Matters Most
Moving People out of Danger (B): Special Needs Evacuations from Gulf Coast Hurricanes
Valley Systems (A)
Thought Leader Interview: Elliot Eisner
Nordstrom: Expansion into Canada
Value Innovation By Chobani
